SynthesisFrontiers in pharmacology2025
A systematic review and meta-analysis on the efficacy and safety of finerenone in the progression of heart failure.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Finerenone Beyond Diabetic Kidney Disease: Emerging Evidence and Potential Systemic Implications.Journal of clinical medicine · 2026Review
- Finerenone Across the Cardiovascular-Kidney-Metabolic Continuum: From Mechanistic Rationale to Clinical Positioning-A Narrative Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Finerenone, a kind of mineralocorticoid receptor antagonist (MRA), may benefit heart failure (HF) patients as MRAs are established effective therapies for HF. Many studies have confirmed the drug's effectiveness in treating kidney disease. However, the efficacy and safety of finerenone on HF remain unclear. Therefore, this systematic review and meta-analysis was conducted to assess the preliminary efficacy and safety of finerenone in HF treatment. Methods: This systematic review and meta-analysis included randomized controlled trials (RCTs) involving adults with heart failure, diabetes, or chronic kidney disease (CKD) treated with finerenone. The major outcomes were the risk of HF occurrence or worsening and hospitalization due to HF, whereas the secondary outcomes included cardiovascular death and all-cause mortality. Data were extracted and analyzed following PRISMA guidelines, and risk of bias was evaluated using the Cochrane Handbook. This review was registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42024612580). Results: Six RCTs (n = 21, 295) were included. Finerenone was associated with a lower risk of HF occurrence or worsening and hospitalization due to HF than placebo [risk rate (RR): 0.81; 95% confidence interval (CI): 0.76-0.87; P < 0.00001]. However, no prominent differences were found in cardiovascular death (RR: 0.93; 95% CI: 0.83-1.03; P = 0.18) or all-cause mortality (RR: 0.94; 95% CI: 0.87-1.02; P = 0.11). Safety analysis indicated a reduced risk of serious adverse reactions (RR: 0.93; 95% CI: 0.90-0.98; P = 0.005) and discontinuation of the study medication due to adverse events (RR: 1.14; 95% CI: 1.01-1.30; P = 0.04). Conclusion: Finerenone appears to decrease the risk related to HF occurrence and progression, particularly in patients with CKD and diabetes, but its impact on overall mortality remains uncertain. The potential benefits need to be balanced against the risk of adverse effects. Further research is essential to explore optimal dosing and treatment duration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.